JP2024546951A5 - - Google Patents

Info

Publication number
JP2024546951A5
JP2024546951A5 JP2024535951A JP2024535951A JP2024546951A5 JP 2024546951 A5 JP2024546951 A5 JP 2024546951A5 JP 2024535951 A JP2024535951 A JP 2024535951A JP 2024535951 A JP2024535951 A JP 2024535951A JP 2024546951 A5 JP2024546951 A5 JP 2024546951A5
Authority
JP
Japan
Prior art keywords
branched
linear
compound according
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024535951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546951A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/081704 external-priority patent/WO2023114937A2/en
Publication of JP2024546951A publication Critical patent/JP2024546951A/ja
Publication of JP2024546951A5 publication Critical patent/JP2024546951A5/ja
Pending legal-status Critical Current

Links

JP2024535951A 2021-12-16 2022-12-15 脂質ナノ粒子に用いるフッ化カチオン性脂質 Pending JP2024546951A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290396P 2021-12-16 2021-12-16
US63/290,396 2021-12-16
PCT/US2022/081704 WO2023114937A2 (en) 2021-12-16 2022-12-15 Fluorinated cationic lipids for use in lipid nanoparticles

Publications (2)

Publication Number Publication Date
JP2024546951A JP2024546951A (ja) 2024-12-26
JP2024546951A5 true JP2024546951A5 (https=) 2025-12-12

Family

ID=85157138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024535951A Pending JP2024546951A (ja) 2021-12-16 2022-12-15 脂質ナノ粒子に用いるフッ化カチオン性脂質

Country Status (8)

Country Link
US (1) US20250059131A1 (https=)
EP (1) EP4448482A2 (https=)
JP (1) JP2024546951A (https=)
KR (1) KR20240122872A (https=)
CN (1) CN118647599A (https=)
CA (1) CA3242399A1 (https=)
IL (1) IL313484A (https=)
WO (1) WO2023114937A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025166325A1 (en) 2024-02-02 2025-08-07 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
TW202543585A (zh) 2024-03-08 2025-11-16 美商健臻公司 脂質奈米粒子
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
WO2025231114A1 (en) 2024-05-01 2025-11-06 Acuitas Therapeutics, Inc. Method of using lipid nanoparticles for intramuscular delivery
WO2025240833A1 (en) 2024-05-17 2025-11-20 Acuitas Therapeutics, Inc. Galnac lipid compounds for use in lipid nanoparticles
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
WO2013086373A1 (en) * 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
HUE060907T2 (hu) 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
PT3313829T (pt) 2015-06-29 2024-07-08 Acuitas Therapeutics Inc Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
MX2020007944A (es) * 2018-02-01 2020-11-24 Tufts College Nanocomplejos similares a los lípidos y sus usos.
CN113387825A (zh) * 2021-06-10 2021-09-14 福州大学 长链烷基酯胺类化合物或含氟长链烷基酯胺类化合物及其公斤级制备方法

Similar Documents

Publication Publication Date Title
JP2024546951A5 (https=)
JP2024546950A5 (https=)
JP2024546952A5 (https=)
JP7241869B2 (ja) 脂質組成物
JP2022544652A5 (https=)
JP2022539089A5 (https=)
JP2017522376A5 (https=)
JP2022505234A5 (https=)
JP2024542260A5 (https=)
WO2019235635A1 (ja) 化合物またはその塩および脂質粒子
JP2024542188A5 (https=)
JP2018521052A5 (https=)
JP6261011B2 (ja) 眼疾患処置薬
JP2012507522A5 (https=)
JPH05501861A (ja) 界面活性剤の性質を有するフッ素およびリン含有両親媒性分子
JP2010506854A5 (https=)
JP2023513698A5 (https=)
JP2011500818A5 (https=)
JP2025534494A (ja) イオン化可能な脂質及びその使用
CN121889371A (zh) 脂质及其组合物
JP2011513317A5 (https=)
JP2024511067A5 (https=)
KR20110126631A (ko) 세라마이드-유사체 대사물
JP2022521474A5 (https=)
JP2002533336A5 (https=)